Article
Genome-wide interaction study with body mass index identifies CYP7A1 and GIPR as genetic modulators of metabolic dysfunction-associated steatotic liver disease.
Clinical and molecular hepatology - 1 Oct 2025
Jamialahmadi Oveis, Mujica Endrina, Morris Lowri, Mancina Rosellina Margherita, Ciociola Ester, Qadri Sami F, Maurotti Samantha, Malvestiti Francesco, Li-Gao Ruifang, Ronzoni Luisa, Tavaglione Federica, Maude Hannah, Allalou Amin, Emmanouilidou Anastasia, Vespasiani-Gentilucci Umberto, Rosendaal Frits Richard, Yki-Järvinen Hannele, Cebola Inês, Valenti Luca, Hoed Marcel den, Romeo Stefano
Abstract excerpt
BACKGROUND/AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) may progress to liver inflammation, fibrosis, cirrhosis and hepatocellular carcinoma. So far, genome-wide association studies explain a small fraction of MASLD heritability. METHODS: We sought to identify novel genetic determinants of MASLD by exploring interactions between genetic variants and body mass index (BMI). First, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.